OmniComm Systems Introduces AutoEncoder, a Coding Solution for Clinical Trials
Fort Lauderdale, FL, May 07, 2018 (GLOBE NEWSWIRE) -- OmniComm Systems, Inc. (OTCQX: OMCM), a global provider of clinical data management technology, today announced the launch of OmniComm AutoEncoder, a user-friendly tool for coding clinical data against medical dictionaries. OmniComm will showcase and demonstrate AutoEncoder at industry events around the globe, including Innovation Forum Europe, June 7-8 in Bonn, DIA China in Beijing on May 23-25, and DIA 2018 in Boston on June 24-28.
“We have taken the opportunity to build a state-of-the-art coding tool from scratch,” said Keith Howells, OmniComm’s chief technology officer. “It has sophisticated algorithms, including language-sensitive search capabilities, and it features a fresh, intuitive and responsive user interface. Coding professionals are going to feel really at home with this product.”
Coding is a unique and necessary process required by regulators during clinical trials or when monitoring the safety of approved products. Regulatory agencies require that adverse events be coded against the MedDRA dictionary, and that medications be coded against the WHO Drug dictionary. The coding process is performed by specialist medical professionals, who must ensure consistent and accurate decisions based on the content of the source term, any relevant related data, and prior decisions for the trial or drug project.
The OmniComm AutoEncoder provides a modern and sophisticated tool for performing these coding activities. Out of the box, AutoEncoder is fully integrated with OmniComm’s TrialMaster® product for Electronic Data Capture, and its open interfaces also allow for integration with any third-party EDC or safety reporting system.
“We are confident that our cutting-edge coding solution will be well received by the industry,” said Stephen Johnson, president and CEO of OmniComm. “AutoEncoder deploys the latest in technology and intuitive design. We’ve leveraged our previous 10 years of experience offering coding solutions and aligned this new technology to match the changing industry regulations. The result is a functionally rich, easy-to-use, innovative solution that is fully integrated with our TrialMaster EDC solution and easily integrated with third-party EDC and safety systems.”
About OmniComm Systems, Inc.
OmniComm Systems provides a role in enhancing patient lives by shortening time to market of essential life-saving treatments. OmniComm Systems is dedicated to providing the latest eClinical technology enabling the world’s life science organizations to maximize the value of their clinical research investments. OmniComm’s solutions provide better trial oversight and study delivery, connecting patients to better healthcare. OmniComm provides comprehensive solutions for clinical research with an extensive global experience from more than 6,000 clinical trials. Please visit www.omnicomm.com for more information.
Trademarks
OmniComm, TrialMaster and TrialOne are registered trademarks of OmniComm Systems, Inc. Other names may be trademarks of their respective owners.
Contact Info
Kuno van der Post
OmniComm Systems, Inc.
+1.954.473.1254
KvanderPost@omnicomm.com
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
